

SCIENTIFIC ADVISORY COMMITTEE & COLLABORATORS**Regular Access = Knowledge + Insights → leapfrog → PROGRESS**

There are days of triumph, when you need to take a breath, triple-check — validate your progress. Then, there are frustrating ones when you're a little stuck and need a pair of fresh eyes. At Kernal Bio, we're fortunate to have ready access to some of the brightest stars in the world of science and business who serve as advisors and collaborators.

Advisors

Edward Benz Jr, M.D. Medical Oncology	<u>President and CEO Emeritus of Dana Farber Cancer Institute; Harvard Medical School</u>
Art Krieg, M.D. Nucleic Acid Therapeutics	<u>Founder/CEO/CSO of Four Successful Nucleic Acid Companies (Translate Bio, Checkmate Pharmaceuticals, Coley, and Sarepta)</u>
Peter Blume-Jensen LNP, Formulation	<u>Acivon Therapeutics; Former Head of Merck's Oncology Department</u>
Ed DeMore Financing Strategy	<u>Boston Global Bridge Institute; Former Partner at a Merchant Bank, Former Executive at Xerox, Member of Mayor Thomas Menino's Office, Philanthropist</u>
Dean W. Felsner, M.D., Ph.D. Translational Oncology	<u>Director of Stanford Medicine Translational Research and Applied Medicine, Stanford Medical School</u>
Dan Peer, Ph.D. mRNA Delivery	<u>Tel Aviv University Center for Translational Medicine and the SPARK TLV program at TAU</u>
Shobha Vasudevan, Ph.D. Cancer RNA Biology	<u>Massachusetts General Hospital; Associate Professor at Harvard Medical School</u>
Nikolai Slavov, Ph.D. mRNA Translation	<u>Associate Professor at Northeastern University</u>
Umut Eser, Ph.D. Deep Learning	<u>Chief Innovation officer at Doctor Evidence, LLC; Harvard Medical School</u>

Collaborators

Pieter Cullis, Ph.D.	<u>University of British Columbia; Acuitas Therapeutics</u>
Jeroen Pollet, Ph.D.	<u>Baylor College of Medicine</u>
Maria Elena Bottazzi, Ph.D.	<u>Baylor College of Medicine Texas Children's Hospital Center for Vaccine Development; Elsevier's Vaccine</u>

SELECTED SEED ROUND PARTICIPANTS

Kernal Bio funded the expansion of the team with a portion of the \$10.5 million in seed-round funding, led by Hummingbird Ventures, which closed in early 2021. We are very grateful to our investors and are making extraordinary progress toward our goal of clinical trials in human. In addition to the list below, participants also included individuals and other angel investors.

Hummingbird

Hummingbird VenturesY CombinatorFoundersX VenturesCivilization VenturesHOF CapitalGaingelsUncommon DenominatorSAV VenturesAsymmetry Ventures**MEDIA CONTACTS**

caroline@mirepoixllc.com | (781) 771-5579
joel@mirepoixllc.com | (847) 343-0537